Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal carcinoma
2020-002270-26Phase 3Active
- Sponsor
- OncoQuest Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by OncoQuest Inc. Primary endpoint: Progression-free survival. Started Nov 2020; status: active.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-002270-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002270-26.